selpercatinib


( Last Updated : May 5, 2022)
Generic Name:
selpercatinib
Project Status:
Active
Therapeutic Area:
Thyroid cancer
Manufacturer:
Eli Lilly Canada Inc.
Brand Name:
Retevmo
Project Line:
Reimbursement Review
Project Number:
PC0264-000
Tumour Type:
Head and Neck
NOC Status at Filing:
Post NOC

Details


Manufacturer Requested Reimbursement Criteria1:
Retevmo is indicated as monotherapy for the treatment of: RET-mutant medullary thyroid cancer in adult and pediatric patients 12 years of age and older with unresectable advanced or metastatic disease.
Submission Type:
Initial
Fee Schedule:
Schedule A
Indications:
Retevmo is indicated as monotherapy for the treatment of: RET-mutant medullary thyroid cancer in adult and pediatric patients 12 years of age and older with unresectable advanced or metastatic disease.
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Key Milestones2

Call for patient/clinician input open 14-Sep-21
Call for patient/clinician input closed 05-Nov-21
Clarification:

- Patient input submission received from GroupCanCertainty, Canadian Cancer Society's patient panels and networks, and Thyroid Cancer Canada patient networks

Submission received 29-Oct-21
Submission accepted 17-Nov-21
Review initiated 18-Nov-21
Draft CADTH review report(s) provided to sponsor for comment 17-Feb-22
Deadline for sponsors comments 01-Mar-22
CADTH review report(s) and responses to comments provided to sponsor 01-Apr-22
Expert committee meeting (initial) 13-Apr-22
Draft recommendation issued to sponsor 27-Apr-22
Draft recommendation posted for stakeholder feedback 05-May-22
End of feedback period 19-May-22